登录新浪财经APP 搜索【信披】查看更多考评等级 2025年11月15日，浙江锦盛新材（维权）料股份有限公司（简称：锦盛新材，代码：300849）发布《关 于公司及相关当事人收到行政处罚决定书的公告》。 经中国证监会浙江监管局查明，当事人涉嫌违法的事实如下：2021年12月 6日，锦盛新材与浙江宏祥建 设工程有限公司（以下简称浙江宏祥）签订《建设工程施工合同》，约定浙江宏祥承包"年产 6，000 万 套化妆品包装容器建设项目"厂房建设（以下简称 6，000 万套项目）。同日，浙江宏祥与阮钟炎签订 《工程项目内部承包经营协议》，将上述厂房建设交由阮钟炎实际承包。浙江宏祥仅按合同金额的一定 比例收取管理费，阮钟炎控制项目章、自主雇 员建设、自主采购与付款、自主与锦盛新材对接请款、 自负盈亏，实质系阮钟炎与锦盛新材开展业务。 经查，阮钟炎系锦盛新材实际控制人兼董事长阮荣涛 的侄子，阮荣涛正因为其与自己的叔侄关系，才指定将6，000万套项目交由阮钟炎实际承包，并要求浙 江宏祥在合同签订等安排中予以配合。根据《上市公司信息披露管理办法》第六十二条，阮钟炎系锦盛 新材关联自然人，上述交易构成关联交易。2022年上述关联交 ...

Core Viewpoint - Baiyin Nonferrous Metals Group Co., Ltd. has been penalized by the China Securities Regulatory Commission (CSRC) for significant omissions in its financial disclosures regarding 3 billion yuan in wealth management products purchased between August 2017 and March 2018, which were not recovered on time [2]. Group 1: Regulatory Actions - The CSRC's Gansu Regulatory Bureau found that Baiyin Nonferrous failed to disclose specific details about the 30 billion yuan wealth management products in its annual reports from 2019 to 2024, leading to a major omission in information disclosure [2]. - As a result of these violations, the CSRC has ordered Baiyin Nonferrous and responsible personnel to rectify the situation, issued warnings, and imposed fines [2]. Group 2: Legal Implications for Investors - Investors who suffered losses due to Baiyin Nonferrous's information disclosure violations may seek civil compensation, which includes investment differences, commissions, stamp duties, and interest losses [3]. - A lawyer from Shanghai Hanlian Law Firm is collecting claims from investors who purchased Baiyin Nonferrous securities between April 30, 2020, and September 10, 2025, and either sold or continued to hold them after September 11, 2025 [3]. Group 3: Claim Registration Process - Investors interested in filing claims must provide specific documentation, including a copy of their ID, original securities account confirmation, and original transaction records stamped by their brokerage [4].

Core Viewpoint - Dongni Electronics is facing administrative penalties from the China Securities Regulatory Commission (CSRC) for failing to disclose significant contract progress and for falsifying financial reports, which has led to potential investor compensation claims [1][4]. Group 1: Disclosure Issues - Dongni Electronics failed to timely disclose the inability to meet the delivery schedule of a major contract worth 675 million yuan, which accounts for 51.84% of its latest audited revenue [2]. - The company only reported a 6.74% completion rate of the contract by the end of October 2023, with the delayed disclosure occurring on January 6, 2024 [2]. Group 2: Financial Misstatements - The company inflated its profit figures by 38.63% and 70.95% in its 2022 annual report and 2023 semi-annual report, respectively, due to misclassification of expenses and inadequate provisions for inventory impairment [3]. - Specific misstatements included misclassifying research and development expenses as inventory and failing to account for related party transactions [3]. Group 3: Legal and Compensation Implications - Following the CSRC's findings, Dongni Electronics and responsible personnel are subject to warnings and fines [4]. - A law firm is actively seeking to represent affected investors who purchased Dongni Electronics' securities between March 11, 2023, and January 5, 2024, for potential compensation claims [5].

Core Points - The China Securities Regulatory Commission (CSRC) has issued a notice of administrative penalty to Sanqi Interactive Entertainment, citing multiple violations related to false disclosures in annual reports from 2014 to 2021 [1] - The violations include misrepresentation of shareholder holdings, failure to disclose related party transactions, and significant omissions in financial reporting [1] - The CSRC plans to impose penalties on Sanqi Interactive, its actual controller and chairman Li Weiwei, and other responsible personnel, including warnings and fines [1] Summary by Sections Company Violations - Sanqi Interactive Entertainment's annual reports from 2014 to 2020 contained false records regarding shareholder holdings [1] - The 2018 annual report failed to disclose the acquisition of Jiangsu Aurora's equity as a related party transaction, representing a major omission [1] - The indirect acquisition of Guangzhou Sanqi's equity in 2020 was also classified as a related party transaction, with false disclosures in a temporary announcement and the annual report [1] - Annual reports from 2018 to 2021 did not disclose related party transactions with Hainan Liyuan and other companies, indicating significant omissions [1] Legal Implications - Following the CSRC's notice, a lawyer from Shanghai Hanlian Law Firm is gathering claims from investors who purchased Sanqi Interactive's securities between March 31, 2015, and June 27, 2023, for potential civil compensation [2] - Investors who suffered losses can register for claims if they sold or continued to hold their securities after June 28, 2023 [2] - The conditions for claims may be adjusted based on the final conclusions of the CSRC's administrative penalties and court rulings [3]

Core Viewpoint - Suzhou Qingyue Optoelectronics Technology Co., Ltd. is under investigation by the China Securities Regulatory Commission (CSRC) for suspected false reporting of financial data, which may lead to civil compensation liabilities for affected investors [1]. Group 1: Investigation and Legal Implications - The CSRC has decided to initiate an investigation against Qingyue Technology due to allegations of false financial reporting, as per the Securities Law of the People's Republic of China [1]. - Investors who have suffered losses due to the alleged securities fraud can file civil compensation claims against the company, its major shareholders, and relevant executives [1]. - A lawyer from Shanghai Hanlian Law Firm is collecting claims from investors who purchased Qingyue Technology's securities before November 1, 2025, and either sold or continued to hold them afterward [2]. Group 2: Claim Conditions and Procedures - The conditions for filing claims include having bought Qingyue Technology's stocks or bonds before November 1, 2025, and selling or holding them after that date [2]. - The final conditions for claims will be adjusted based on the conclusions of the CSRC's administrative penalties and the court's final judgment regarding the legal timeline, compensation subjects, and standards [3]. - Investors must provide specific documentation for claim registration, including a copy of their ID, securities account information, and transaction records [3].

Core Points - Shandong Meichen Technology Co., Ltd. has been penalized by the China Securities Regulatory Commission (CSRC) for financial misconduct involving inflated revenues and profits from 2014 to 2018 [1][2][3] Summary by Sections Company Misconduct - Meichen Technology acquired 100% of Hangzhou Saishi Garden Group Co., Ltd. in September 2014, which led to the latter becoming a wholly-owned subsidiary [2] - From 2014 to 2018, Saishi Garden inflated construction costs and completion percentages through false procurement and sales, resulting in a total inflated revenue of 1,437.78 million yuan and inflated profits of 657.96 million yuan [2] - The inflated revenues and profits for each year were as follows: - 2014: Revenue inflated by 23.66 million yuan (2.06% of reported revenue), profit inflated by 22.93 million yuan (17.91% of reported profit) - 2015: Revenue inflated by 372.64 million yuan (20.67%), profit inflated by 188.54 million yuan (75.64%) - 2016: Revenue inflated by 725.61 million yuan (24.60%), profit inflated by 259.58 million yuan (49.78%) - 2017: Revenue inflated by 215.19 million yuan (5.53%), profit inflated by 117.43 million yuan (15.49%) - 2018: Revenue inflated by 100.68 million yuan (2.88%), profit inflated by 69.49 million yuan (15.58%) [2] Regulatory Actions - The CSRC's Shandong Regulatory Bureau has ordered Meichen Technology and responsible personnel to rectify the situation, issue warnings, and impose fines [2] - The company has faced multiple notifications from the CSRC regarding the investigation and penalties, with the latest being an administrative penalty decision [3] Investor Implications - Investors who suffered losses due to the company's misconduct can seek civil compensation, which includes investment differences, commissions, stamp duties, and interest losses [3] - A lawyer from Shanghai Hanlian Law Firm is collecting claims from affected investors who purchased Meichen Technology's securities between March 12, 2015, and March 31, 2025 [3]

Core Viewpoint - Shanghai Xinyang Semiconductor Materials Co., Ltd. has been found to have violated information disclosure regulations, leading to potential civil compensation claims from affected investors [1][2]. Group 1: Regulatory Findings - The China Securities Regulatory Commission (CSRC) discovered that Shanghai Xinyang failed to recognize the value and fair value changes of a financial derivative product worth 100 million yuan, resulting in an inflated net profit of approximately 13.53 million yuan for the first quarter report of 2024 [1]. - The company disclosed a correction announcement on August 17, 2024, regarding its first-quarter report for 2024, which did not include the necessary financial information related to the derivative [1]. Group 2: Investor Compensation - A lawyer from Shanghai Hanlian Law Firm is collecting claims from investors who purchased Shanghai Xinyang's securities between April 20, 2024, and August 16, 2024, and either sold or continued to hold them after August 17, 2024 [2]. - The conditions for compensation claims will be adjusted based on the conclusions of the CSRC's administrative penalties and the final court rulings regarding the legal time points, compensation objects, and standards [2]. Group 3: Legal Process and Requirements - The progress of civil compensation lawsuits will not be affected by whether the company is delisted, but entering bankruptcy proceedings may significantly impact the lawsuit's progress [3]. - Investors wishing to register for compensation must provide specific documentation, including a copy of their ID, original securities account information confirmation, and original transaction records [3].

Group 1 - Hainan Huate Technology announced the termination of the "Computing Power Service Agreement" with Hangzhou X Company, citing significant changes in market conditions since the contract was signed [1] - The original agreement, signed on March 5, 2025, was valued at 3.69 billion yuan (including tax) for a service period of five years, but no purchase orders were received since the signing [1] - The Shanghai Stock Exchange issued a regulatory letter to Hainan Huate regarding the termination of the major contract, emphasizing the need for compliance from the company and its executives [1] Group 2 - Hainan Huate is facing potential legal actions from investors due to alleged violations of information disclosure laws, with a lawyer actively seeking to represent affected investors for compensation claims [2] - The conditions for investor compensation claims include purchases made between March 5, 2025, and September 30, 2025, with claims possible for those who sold or continued to hold shares after October 1, 2025 [2] - Legal proceedings may be influenced by the company's administrative penalties, and investors are advised to consider these factors before initiating lawsuits [3]

Core Viewpoint - Shanghai Magical Pharmaceutical Co., Ltd. has been found to have violated information disclosure regulations, leading to administrative regulatory measures from the China Securities Regulatory Commission (CSRC) [1] Summary by Sections Company Violations - In 2023, the company misappropriated sales expenses amounting to 44,838,280 yuan through a halted "basic drug promotion plan" and created fictitious accounts receivable, which had already been fully impaired [1] - This led to incorrect information being disclosed in the company's 2023 annual report, violating Article 3, Paragraph 1 of the "Administrative Measures for Information Disclosure by Listed Companies" [1] Regulatory Actions - The CSRC's Shanghai Bureau has mandated corrective actions for the company and issued warning letters to individuals including Zhang Tao Tao, Feng Bin, and Chen Zhimian [1] Legal Implications for Investors - Investors who suffered losses due to the company's violations can seek civil compensation, which includes investment differences, commissions, and stamp duties [2] - A lawyer is actively recruiting affected investors for litigation against the company, specifically targeting those who purchased shares between April 29, 2024, and September 26, 2025 [2] Litigation Process - While investors can file lawsuits without prior administrative penalties, the lack of thorough investigation may increase the risk of losing the case [3] - The status of the company, including potential delisting or bankruptcy, may affect the litigation process but does not halt it [3] Required Documentation for Claims - Investors must provide specific documents for compensation claims, including a copy of their ID, securities account information, and transaction records [3]

Core Viewpoint - Hunan Nanxin Pharmaceutical Co., Ltd. is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of annual report information disclosure laws, which may lead to civil compensation claims from affected investors [1]. Group 1: Investigation and Legal Actions - The CSRC has decided to initiate an investigation against Nanxin Pharmaceutical due to alleged violations of information disclosure laws as per the Securities Law and Administrative Penalty Law of the People's Republic of China [1]. - Investors who have suffered losses due to the company's alleged fraudulent activities can file civil compensation claims, which may include investment differences, commissions, and stamp duties [1]. - A lawyer from Shanghai Hanlian Law Firm is actively seeking to represent affected investors in compensation lawsuits against Nanxin Pharmaceutical [1]. Group 2: Compensation Conditions - The conditions for compensation claims include investors who purchased Nanxin Pharmaceutical's stocks or bonds before October 1, 2025, and either sold or continued to hold them after this date [1]. - The final conditions for compensation will be adjusted based on the conclusions of the CSRC's administrative penalties and the court's final judgment regarding the legal timeline, compensation targets, and standards [2]. - Investors are advised that while they can initiate lawsuits without the administrative penalty decision, doing so may carry risks of losing the case due to limited investigative means [2]. Group 3: Documentation for Claims - Investors wishing to register for compensation must provide specific documentation, including a copy of their ID, original securities account opening confirmation, and original transaction records from the first purchase to the present [2].